Compared with the general population, CHR individuals are more likely to be prescribed atypical antipsychotic (AT) medications (Cadenhead et al., 2010; Walker et al., 2009) , and these medications have been associated with elevated weight gain, a side effect that is especially distressing for youth (Allison et al., 2009; De Hert, Dekker, Wood, Kahl, & Holt, 2009) . Similarly, heightened stress exposure can lead to the development of maladaptive eating behaviours to manage stress (Adam & Epel, 2007) . Stress-induced eating can influence underlying neurobiology and lead to increased weight (Yau & Potenza, 2013) . To date, however, the joint or potential interactive effects of ATs and stress on weight gain in CHR youth have not been examined.
| Mechanisms underlying weight gain from ATs
There are multiple mechanisms that may subserve the increase in weight among those taking ATs, including the role of serotonergic 5-HT2c receptors, D2 antagonists, and muscarinergic M3 antagonists (Nasrallah, 2003; Starrenburg & Bogers, 2009 ). The hypothesis with the strongest research support pertains to analogue interactions with histamine binding sites on neurons in the hypothalamus (Kraus et al., 1999; Kroeze et al., 2003; Masaki et al., 2004; Matsui-Sakata, Ohtani, & Sawada, 2005; Melkersson, Hulting, & Brismar, 2000; Starrenburg & Bogers, 2009) . Notably, the average amount of weight gained while taking ATs varies by type, with clozapine and olanzapine shown to be associated with the most weight gain (Bak, Fransen, Janssen, van Os, & Drukker, 2014; Allison et al., 1999; Maayan & Correll, 2011; Nasrallah, 2003; Starrenburg & Bogers, 2009 ). Ziprasidone, aripiprazole, and quetiapine have been associated with relatively less weight gain (Bak et al., 2014; Nasrallah, 2003) . Despite this, switching type of medication has not been found to be helpful in reducing weight (Bak et al., 2014) .
AT-associated weight gain and its consequences are well-documented in patients with psychosis (Allison et al., 1999; Bak et al., 2014; Maayan & Correll, 2011; Newcomer, 2005) . Weight gain from AT use can contribute to decreased medication compliance (Cooper & Moisan, 2007; Valenstein et al., 2004; Weiden, Mackell, & McDonnell, 2004 ) and, in turn, higher rates of relapse and hospitalization in these patients (Sun, Liu, Christensen, & Fu, 2007) .
| The role of stress in weight gain
It is well-established that stress negatively impacts physical (Boardman, 2004 ) and mental (Aneshensel & Sucoff, 1996; H. A. Turner, Finkelhor, & Ormrod, 2006) health. Biological and behavioural factors are involved in the relation of stress with weight (Wilson & Sato, 2013; van Jaarsveld, Fidler, Steptoe, Boniface, & Wardle, 2009 ). For example, stress hormone (i.e., cortisol) secretion can alter neurobiological processes, thereby contributing to increased vulnerability to maladaptive eating behaviours. As noted, individuals at CHR for psychosis experience a greater number of life events stressors and have greater sensitivity to such stressors (Trotman et al., 2014) . Therefore, it is particularly important to examine the role of stress and increased weight in this population.
Sympathetic nervous system reactions and cortisol release are assumed to mediate the link between stress and weight gain. Cortisol, a glucocorticoid, in the presence of insulin, promotes an increase in the amount of fat deposits in the abdomen, as there are increased glucocorticoid receptors in this area (Yau & Potenza, 2013) . Notably, intra-abdominal fat is most related to stress and metabolic problems (Björntorp, 2001) . Glucocorticoids also interact with other hormones -inhibiting the action of insulin and leptin that regulate hunger and satiety. Glucocorticoid release also increases neuropeptide Y, a hormone that counteracts the stress response and increases appetite, making it a potential facilitator in "stress eating" or "emotional eating" (Adam & Epel, 2007) . When these homeostatic mechanisms that control weight are out of balance, eating behaviour is altered.
These biological processes also contribute to increase eating through interactions with the brain's reward system. Specifically, increased glucocorticoids augment cravings for highly palatable foods that engage the reward system via opioid and dopaminergic processes.
It has been hypothesized that, over time, persistent stimulation of dopaminergic systems promotes desensitization, making one feel as if they need more highly palatable foods to feel satisfied (Adam & Epel, 2007; Berridge, 2009; Yau & Potenza, 2013) .
In addition to triggering the above biological processes, it is well established that increased stress leads to eating as a method for coping with negative affect (Adam & Epel, 2007) . This has been demonstrated in adult (van Strien, Konttinen, Homberg, Engels, & Winkens, 2016) , child (Jenkins, Rew, & Sternglanz, 2005) , clinical (Goossens, Braet, Van Vlierberghe, & Mels, 2009) , and nonclinical samples (Webber, Hill, Saxton, Van Jaarsveld, & Wardle, 2009) . Further, individuals with mental illness are more likely to engage in other behaviours that impact weight (e.g., smoking) and are less likely to have access to resources that afford physical activity or the consumption of healthy foods (De Hert et al., 2009 ).
| Present study
In sum, individuals at CHR for psychosis are more likely to be exposed to two factors that contribute to weight gain; the use of AT medications and heightened stress. Excessive weight gain has a variety of adverse health consequences for youth, and as noted above, ATinduced weight gain is a primary cause of treatment noncompliance.
To date, there has been no published research that simultaneously examines the relations of ATs and stress exposure with weight in clinical samples, including CHR youth. Such research is important, because CHR individuals may be at even greater risk for adverse effects of weight gain, as they are in a period of heightened developmental transition and experience a higher rate of stressful life events. Further, noncompliance resulting from weight gain may jeopardize subsequent medication compliance and worsen prognosis in those at greatest risk for psychosis. Thus, research on factors that moderate AT-related weight gain is especially important in CHR youth.
The current cross-sectional study examines AT use and weight in a large sample of youth at CHR for psychosis. Both the direct and potential moderating effects of life-event stress on the relationship between ATs and weight are tested. It is predicted that (a) both AT use and self-reported stress will be positively related to weight in CHR subjects, and (b) stress will moderate the positive relationship between AT use and weight, such that the strength of the relation between ATs and weight will be amplified by higher levels of stress exposure.
All participants were part of Phase 2 of the North American Prodrome Longitudinal Study (NAPLS-2), a multisite, longitudinal study that aims to enhance the prediction of psychosis in CHR subjects and shed light on the neural mechanisms of conversion. Individuals were excluded from the study if they had an Axis I psychotic disorder, an IQ below 70, history of a central nervous system disorder, or a substance use disorder (Addington et al., 2012) . For more detailed information about the study procedures and sample characteristics, see Addington et al. (2012) . The present study included 534 CHR participants in NAPLS-2 for whom baseline data were available on current psychotropic medication, body weight, and life-event stress.
| Assessment procedures
As part of the NAPLS-2 protocol, each participant received an extensive diagnostic assessment, and information on past and current medical history, including psychotropic medication, was obtained (Addington et al., 2012) .
| Measures

| Diagnostic assessment
The Structured Interview for Psychosis-Risk (originally titled Prodromal) Syndromes was used to determine CHR status and includes the Scale of Psychosis-Risk (originally titled Prodromal) Symptoms. Symptoms are rated on a scale of 0 (absent) to 6 (very severe and psychotic).
A detailed description of how CHR is determined can be found in previous reports (Miller et al., 1999; Miller et al., 2002) .
| Psychotropic medication
Current psychotropic medication data were coded by specific medication type and then aggregated by class. The primary classes of psychotropic medication in the sample were ATs and antidepressants (ADs), as described in Cadenhead et al. (2010) . Some participants were also receiving psychological treatment while enrolled in the study (Woodberry et al., 2016) . Medication dosage data were also collected.
In previously published papers, detailed descriptions of the procedures for calculating chlorpromazine equivalents (Leucht et al., 2014) and the mean values for the NAPLS CHR subsamples are provided (Woods, 2003) . Because medication dosage information could not be established for all participants receiving one or more psychotropic, the present study examined the presence/absence (i.e., "on/off") of medication rather than dosage. Weight (in pounds) was obtained via participant report.
| Life-event stress
A modified version of the Life Events Scale (Dohrenwend, Krasnoff, Askenasy, & Dohrenwend, 1978) , a standard self-report measure of stress, was administered. The modified scale contained 59 items about events that could potentially occur in the adolescent/young adult age range included in the sample. Participants reported the frequency with which each event occurred and rated how stressful the event was on a scale from 1 (not stressful) to 7 (highly stressful).
For the present study, the summed severity scores were used. The Life Events Scale allows for the derivation of four subscale scores for life events. The dependent life events subscale contains items that tap issues that are potentially secondary to the participant's symptoms (e.g., interpersonal conflicts). The independent life events subscale contains items that tap issues not likely to be due to participant illness (e.g., death/illness of a friend). The desirable life events subscale contains items that are considered to tap life events that are generally positive or desirable (e.g., initiation of a new relationship). This is in contrast to the undesirable life events subscale that contains items that are thought to tap life events that are considered to be negative or undesirable (e.g., was victim of a crime; Dohrenwend et al., 1978) . The subscales include overlapping items. For example, an item can be both undesirable and independent (i.e., family member dies). In the analyses presented below, the four scores described above were used to examine the main and interactive effects of stress. Subscales were assessed separately in order to better assess subtypes of the participants' reported stress experience.
| Statistical analyses
Statistical analyses were conducted with IBM SPSS Statistics 21 (SPSS Inc., Chicago, Illinois). Frequency analyses were used to determine the demographic composition of the sample. Chi square analyses were used to test for group differences in demographic variables and medication status. Bivariate correlations were used to assess the relation between stress subscales and weight. Because those at CHR for psychosis are often prescribed AD and AT medications (Walker et al., 2009 ) and AD medications have also been linked to weight changes (Serretti & Mandelli, 2010) , all analyses were performed for both ATs and ADs, the majority of which were selective serotonin reuptake inhibitors . Analyses of covariance, all controlling for age, were used to analyse weight differences for those on and 
| Demographics
Demographic information for those on and off (on/off) atypical ATs and ADs are presented in Table 1 . There were significant differences between those on/off ATs in weight, F(1, 531) = 4.55, p = .033, and age, t(532) = 2.27, p = .023, in that those on ATs weighed more and were younger. There was also a significant sex difference between those on/off ATs, χ 2 (1) = 3.94, p = .047, and between racial group categories, χ 2 (9) = 18.78, p = .027, such that males were more likely to be on ATs compared with females, and Caucasians were more likely to be on ATs compared with other racial groups.
As might be expected for CHR individuals, there were significant differences in the use of other psychotropic medication between those on/off ATs, such that those on ATs were also more likely to be on ADs, χ (1) = 8.16, p = .004. However, as previously reported, the rates of use of mood stabilizers, stimulants, and benzodiazepines were too low to permit reliable tests of their relation with weight .
| Correlation analyses
The results of correlational analyses (one-tailed significance) are presented in Table 2 . For those taking ATs, there were significant positive correlations between weight and dependent life events, r = .257, For those taking ADs, there were no significant correlations between weight and stress variables. For those not taking ADs, there was a modest but significant correlation between dependent life event stress and weight, r = .113, p = .029.
| Analysis of covariance
When controlling for age, there was a significant weight difference as a function of AT medications, F(1, 1) = 4.55, p = .03, partial ŋ2 = .009, power = .56. However, when controlling for both age and sex, there was not a significant weight difference for males and females nor across the age spectrum as a function of AT medications, F(3, 1) = 2.43, p = .11, partial ŋ2 = .005, power = .34. There was no significant weight difference between those on/off AD medications when controlling for age and sex, F(3, 1) = 1.43, p = .23, partial ŋ2 = .003, power = .22.
| Regression analyses to test for main and interaction effects
Results of the multiple regression analyses, with weight as the dependent variable, are presented in Table 3 . In testing the relation of dependent life events and AT use with weight, the overall variance Note.
*indicates significant difference between those "on" and "off" atypical antipsychotics/antidepressants for that particular variable.
explained by Block 1 (controlling for age, sex, race, and AD use) was significant, with age and sex being significant independent predictors, F(4, 501) = 32.39, p < .001. The R 2 change with the addition of Blocks 2 (AT use; F(1, 500) = 2.35, p = .063, R 2 = .004) and 3 (dependent life events; F(1, 499) = .00, p = .982, R 2 = .000) did not result in a significant increase in the variance explained in predicting weight. The addition of the interaction term (AT use × dependent life events) in the fourth block, however, did result in a significant increase in the variance explained, F(1, 498) = 2.74, p = .049, R 2 = .004. As reflected in the results of the correlational analyses presented above and as shown in Figure 1a , this was due to a stronger relation between dependent life event stress and weight among those on ATs.
Similarly, in the regression using desirable life events, ATs, and their interactions as the predictors, the interaction term in the fourth block did result in a significant increase in the variance explained, F(1, 508) = 3.68, p = .02, R 2 = .006 (Figure 1b) .
In contrast to the above findings, after controlling for age, sex, race, and AD use, there was no significant main or interactive effect of either independent life events or undesirable life events with ATs in the prediction of weight.
When the same regression analyses were conducted to test for the effect of ADs and stress in the prediction of weight, there were no significant main effects of ADs or interactions between stress and AD use with dependent life events, F(1, 498) = .024, p = .43, independent life events, F(1, 488) = .002, p = .48, desirable life events, F(1, 508) = .313, p = .28, or undesirable life events, F(1, 500) = .040, p = .421.
Lastly, in order to determine whether the duration of AT exposure was relevant to weight, bivariate correlations and regression analyses were conducted with months of exposure as a covariate. In this sample, duration of AT use was not correlated with weight (r = .065, p = .13) nor did controlling for AT duration substantively change the study findings (Dependent: t = 1.62, p = .05; Independent: t = .132, p = .44; Desirable: t = 1.85, p = .03; Undesirable: t = 1.13, p = .12).
| DISCUSSION
The present investigation examined the relationships among stress, AT use, and weight for those at CHR for psychosis. Contrary to prediction, after controlling for demographic variables and AD use, there was no significant main effects of ATs or the stress indices on weight.
However, consistent with prediction, three of the four life-event stress indices, desirable life events, dependent life events, and .079 (n = 423) .067 (n = 131) .113* (n = 376) 2. Independent life events .133 (n = 86) .063 (n = 429) .041 (n = 133) .075 (n = 384) 3. Desirable life events .247* (n = 88) .053 (n = 429) .078 (n = 133) .076 (n = 384) 4. Undesirable life events .230* (n = 85) .065 (n = 424) .082 (n = 132) .085 (n = 377) **p < .01. *p < .05.
Note. Tests are one-tailed.
weight in the CHR sample on an AT. This is plausible given that the contextual nature of actual stressors vary (Park & Folkman, 1997) and that individual differences influence how one experiences stressors (Watson, 1988) .
Given that individuals at CHR for psychosis experience more life events stressors and rate them as more stressful compared with control populations (Trotman et al., 2014) , one may expect heightened stress in response to various contextual factors. For example, CHR individuals are most likely to be in adolescence and young adulthood, a time period that is known for being one of great transition and change (Jankord et al., 2011; Lenz, 2001) . Even, for individuals not at CHR, change and transition is often experienced as stressful (Almeida & Wong, 2009) . Therefore, one could surmise that any type of event, positive or negative, could bring about stress that is experienced more strongly in individuals at CHR.
Further, an individual's level of self-efficacy, or one's belief that they have the ability to manage stressors or transitions, may impact their ability to manage such stressors (Jerusalem & Mittag, 1995) .
Levels of self-efficacy vary greatly in individuals with severe mental illness (Corrigan & Watson, 2002) . Similarly, according to the cognitive-relational stress theory, interindividual differences in stress perception can greatly impact how one is able to manage positive and negative life transitions (Lazarus & Folkman, 1987) . This highlights the possibility of contextual variation in the frequency and intensity of endorsed stressors in this group and explains why the pattern of heightened stress due to common stressors may not be as predictable.
Finally, it is also important to consider the impact that increased weight may have on life stress, particularly in adolescents with prodromal symptoms that may already have impaired tolerance to common stressors. Being, or believing that, one is of increased weight may exacerbate subjective distress in response to interpersonal stressors.
| Clinical utility
Findings from this study suggest that more attention should be given to current psychosocial stressors that patients prescribed ATs may experience. The acquisition of behavioural strategies to cope with stress in adaptive ways, such as with exercise, meditation, and perhaps stimulus control around food management, may help mitigate the amount of weight gained while taking AT medications (Duncan, Davison, Remington, & Faulkner, 2017) . Notably, previous research suggesting that changing the type of AT medication does not result in less weight gained (Bak et al., 2014) highlights the potential role that behaviour also plays in the acquisition of excess weight, suggesting that behavioral interventions may be particularly useful.
Further, the use of cognitive strategies by CHR individuals may also be helpful as a way to manage stressors (Morrison et al., 2004) .
Indeed, studies suggest that cognitive and behavioural interventions can aid in reducing weight in individuals with psychosis taking ATs.
For example, Weber and Wyne (2006) found that weight loss was attained after a 16-week cognitive/behavioural intervention for weight loss in individuals with schizophrenia currently taking an AT.
Stress management was a module in the programme (Weber & Wyne, 2006) . Further, Centorrino et al. (2006) found a significant reduction in weight in a sample of individuals diagnosed with schizophrenia or schizoaffective disorder and currently being treated with an AT medication, who were enrolled in a 24-week diet and exercise programme (Centorrino et al., 2006) . Additionally, treatment modalities such as acceptance and commitment therapy may also be useful for this clinical group, as it promotes mindfulness in the experience of negative emotions (i.e., stress) and focusing attention on achieving valued goals (Gaudiano & Herbert, 2006) .
| Strengths and limitations
The NAPLS project is one of the largest investigations of CHR for psychosis in the world, making this an ideal sample in which to examine the interaction between the use of ATs and the experience of stress in affecting weight. Further, the analysis of these processes in individuals identified early in potential illness progression strengthens the argument for the potential utility of early intervention to decrease stress and weight gain.
However, this study does have limitations. Height was not assessed or reported for this sample, so body mass index (BMI) could
Moderation analyses for number of (a) dependent life events and (b) number of desirable life events not be calculated. BMI is considered a more standardized metric of weight, especially in this age range. Adjusting for effects of age and sex, both of which typically correlate with height and weight, mitigated this limitation to some degree. Further, weight was self-reported, and self-report indices of stress were used. Although reliance on self-reported weight is a limitation, it is noteworthy that in the present study, weight was related to demographic variables (i.e., sex and age) in the way that would be expected (age: r = .211, p = .01; sex: t = 8.52, p ≤ .001). Further, most measures of life-event stress are based on self-report because access to archival records of life events is typically not feasible. Nonetheless, previous research indicates that self-reports of stressful events potentially linked to illness onset do not provide as much information as more in depth clinical interviews, as they obtain information on the individual's subjective experience (R. J. Turner & Wheaton, 1995) . Finally, although research shows that the amount of weight gained varies by type of AT prescribed (Allison et al., 1999; Bak et al., 2014; Maayan & Correll, 2011; Starrenburg & Bogers, 2009) , the number of NAPLS subjects on any specific AT is not large enough to perform analyses by AT subtype.
| Directions for future research
With these limitations in mind, future studies are needed to attempt to replicate findings using measured BMI. Longitudinal studies that utilize growth curve analyses would also provide a more reliable measure of weight gain over time as a results of AT use and stress.
Further, more work is needed to understand the degree to which the experience of stress might be related to a poor response to the various weight control interventions that already exist for those who are taking ATs and are gaining weight.
Also of note, nonwhite race has been associated with greater weight gain with some AT medications (Basson et al., 2001) . Research suggests that being a member of a minority group is related to heightened stress (Williams, Yu, Jackson, & Anderson, 1997) and that many minority groups are at heightened risk for obesity and metabolic issues (Clarke, O'Malley, Johnston, & Schulenberg, 2009; Smith et al., 2005) , it is important to examine the interaction of stress and AT use in different racial/ethnic groups to determine whether certain groups are at amplified risk for weight gain.
A potential moderator not assessed in this study is the impact of treatment utilization including therapy (i.e., individual, family, and group). The use of such services could mitigate the direct impact of stress and perhaps even the use of maladaptive coping strategies. Therefore, future research should explore the role of treatment as a potential moderator in the relationship between AT use and stress.
Finally, further research on the relationships among stress, weight, and AT use could include bioindicators of stress, such as cortisol.
Given the relationship between cortisol release and weight gain in individuals without severe mental illness (Adam & Epel, 2007) , as well as the increased cortisol release in CHR individuals (Walker et al., 2013) , one might expect cortisol to mediate the relationship between AT use and increased weight in this group.
| CONCLUSION
In conclusion, the present study provided support for the hypothesis that increased stress and AT use interact to promote greater weight among those at CHR for psychosis. The effect may be based, in part, on heightened change and transition occurring in CHR adolescents.
Longitudinal research is needed to elucidate the specific nature and biological mechanisms in the relationship between stress and weight gain over time. 
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